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Aggressive treatment of colorectal liver metastases (CRLM) after colectomy is increasing in the last two 
decades with reports of improved survival.  Multiple treatment options are available for CRLM but their 
use and utility remains unknown. 
 
Methods:  Using SEER-Medicare linked database (1991-2005), we identified 7131 patients who had 
undergone colectomy with CRLM.  Demographic, clinical and tumor factors were examined as 
determinants of therapy.  Treatment options consisted of surgery (resection, ablation) or 
chemotherapy.  Univariate and multivariate analyses were performed to determine predictors of overall 
survival after colectomy. 
 
Results:  635 patients (8.9%) underwent liver directed surgery defined as either a liver resection 
(n=495), ablation (n=216) or both (n=76) for CRLM.  322 patients (51%) were female and 313 (49%) were 
male.  147 patients (23%) were SES 1, 230 patients (36%) were SES 2, and 258 (41%) were SES 3.  There 
was a survival advantage to receiving liver surgery or chemotherapy in selected patients with CRLM 
(p<0.001).  Of the 635 patients who received liver surgery, 62.7% received chemotherapy within 6 
months of surgery.  Adjusted overall survival after colectomy was greatest in Asian/Other race; poor 
prognostic indicators included increasing comorbidities, advanced age and development of 
complications within one month after liver surgery. 
 
Conclusion:  In the Medicare population, patients with CRLM who receive potentially curative therapy 
such as resection, ablation or chemotherapy experience a substantial survival advantage; despite this 
only 8.9% of patients received directed therapy for their metastasis.  Barriers to treatment and its 
underutilization must be identified to improve survival in patients diagnosed with CRLM after 
colectomy. 
